Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze CBT stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate CBT investment potential.

What is CBT stock price today?

Get real-time CBT stock price, historical data, and price charts on Financhill. Track CBT performance with our advanced analysis tools.

Is CBT a good investment?

Evaluate CBT investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy CBT stock?

To buy CBT stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of CBT?

View detailed market capitalization data and company valuation metrics for CBT on our comprehensive analysis page.

What is the P/E ratio of CBT?

Use our fundamental analysis tools to view CBT P/E ratio and compare valuation metrics with industry peers.

What are CBT earnings?

View CBT earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Cabot Corp. 10K Form

Buy

CBT
Cabot Corp.

Last Price:

$64.09

Seasonality Move:

6.52%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-08-08	10Q	CBT/Cabot Corp. Quarterly
2023-05-09	10Q	CBT/Cabot Corp. Quarterly
2023-02-09	10Q	CBT/Cabot Corp. Quarterly
2022-08-08	10Q	CBT/Cabot Corp. Quarterly
2022-05-09	10Q	CBT/Cabot Corp. Quarterly
2022-02-04	10Q	CBT/Cabot Corp. Quarterly

Receive CBT News And Ratings

See the #1 stock for the next 7 days that we like better than CBT

CBT Financial Statistics

Sales & Book Value

Annual Sales:	$3.7B
Cash Flow:	$182M
Price / Cash Flow:	8.94
Annual Sales:	$29.33
Price / Book:	2.2

Profitability

EPS (TTM):	6.00910
Net Income (TTM):	$372M
Gross Margin:	$946M
Return on Equity:	23.01%
Return on Assets:	9.89%

Cabot Corp. Earnings Forecast

Key Cabot Corp. Financial Ratios

The Gross Profit Margin over the past 46 years for CBT is 25.48%.
The Selling, General & Administrative Expenses for CBT have been equal to 7.00% of Gross Profit Margin.
The Research & Development expenses have been 1.54% of Revenue.
The Interest Expense is 21.24% of Operating Income.
The Net Earning history of CBT is 10.02% of Total Revenues.
Per Share Earnings over the last 46 years have been positive in 17 years.

Cabot Corp. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NYSE
Industry:	Chemicals
Sector:	Materials
Current Symbol:	CBT
CUSIP:	127055
Website:	cabotcorp.com

Debt

Debt-to-Equity Ratio:	0.79
Current Ratio:	1.61
Quick Ratio:	0.98

Price-to-Earnings

Trailing P/E Ratio:	10.73
Forward P/E Ratio:	9

CBT Technical Analysis vs Fundamental Analysis

Buy

Cabot Corp. (CBT) is a Buy

Is Cabot Corp. a Buy or a Sell?

Cabot Corp. stock is rated a Buy

The current Cabot Corp. [CBT] share price is $64.10. The Score for CBT is 55, which is 10% above its historic median score of 50, and infers lower risk than normal.